company background image
HCM logo

HUTCHMED (China) AIM:HCM Stock Report

Last Price

UK£2.63

Market Cap

UK£2.2b

7D

-7.7%

1Y

17.7%

Updated

26 Aug, 2024

Data

Company Financials +

HUTCHMED (China) Limited

AIM:HCM Stock Report

Market Cap: UK£2.2b

HCM Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.

About the company

HCM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 68.4% below our estimate of its fair value
Earnings are forecast to grow 46.66% per year

Risk Analysis

Volatile share price over the past 3 months

HUTCHMED (China) Limited Competitors

Indivior

LSE:INDV

UK£1.2b

Dechra Pharmaceuticals

LSE:DPH

UK£4.4b

Hikma Pharmaceuticals

LSE:HIK

UK£4.5b

Alliance Pharma

AIM:APH

UK£202.2m

Price History & Performance

Summary of all time highs, changes and price drops for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£2.63
52 Week HighUK£3.53
52 Week LowUK£1.90
Beta0.74
11 Month Change-9.93%
3 Month Change-12.33%
1 Year Change17.67%
33 Year Change-51.48%
5 Year Change-27.45%
Change since IPO949.90%

Recent News & Updates

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02
Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11
HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Recent updates

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02
Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11
HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14
HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01
The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

Dec 18
Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Nov 23
HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Aug 24
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

May 10
Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19
With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Shareholder Returns

HCMGB PharmaceuticalsGB Market
7D-7.7%0.1%-0.3%
1Y17.7%20.4%11.6%

Return vs Industry: HCM underperformed the UK Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: HCM exceeded the UK Market which returned 11.6% over the past year.

Price Volatility

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement7.8%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement4.6%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: HCM has not had significant price volatility in the past 3 months.

Volatility Over Time: HCM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20001,970Wei-Guo Suwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM fundamental statistics
Market capUK£2.25b
Earnings (TTM)-UK£31.80m
Revenue (TTM)UK£462.78m

4.9x

P/S Ratio

-70.7x

P/E Ratio

Is HCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM income statement (TTM)
RevenueUS$610.81m
Cost of RevenueUS$658.26m
Gross Profit-US$47.45m
Other Expenses-US$5.48m
Earnings-US$41.97m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin-7.77%
Net Profit Margin-6.87%
Debt/Equity Ratio10.9%

How did HCM perform over the long term?

See historical performance and comparison